2017 American Society of Clinical Oncology Annual Meeting*

June 2-6, 2017; Chicago, Illinois
This program provides coverage of the 2017 ASCO annual meeting with PowerPoint summaries and expert analysis of the key study results with downloadable slidesets. Tumor types covered include skin, hematologic, lung, gastrointestinal, genitourinary, gynecologic, and breast.
John M. Burke, MD
Steven J. Cohen, MD
Matthew D. Hellmann, MD
Sara Hurvitz, MD, FACP
Sagar Lonial, MD
Kathy D. Miller, MD
Farhad Ravandi, MD
Alan P. Venook, MD
Heather Wakelee, MD

ClinicalThought

Look for these important studies at the upcoming Clinical Oncology meeting in Chicago. Be sure to also check our Web site frequently for downloadable PowerPoint slides featuring key presented data.

Sara Hurvitz, MD, FACP Released: May 31, 2017

Breast Cancer

Addition of the CDK4/6 inhibitor abemaciclib to fulvestrant reduced the risk of disease progression by 45%, with an acceptable tolerability profile.

Released: June 7, 2017

Significantly improved PFS and ORR observed with addition of lapatinib to trastuzumab plus investigator-selected aromatase inhibitor.

Released: June 6, 2017

Pembrolizumab monotherapy was well tolerated and active in a subset of pretreated metastatic TNBC patients, with promising preliminary survival results observed in patients with CR, PR, or SD.

Released: June 4, 2017

The addition of ipatasertib to paclitaxel improved PFS for patients with metastatic TNBC, with the greatest benefit observed in a prespecified subgroup analysis of patients with PIK3CA/AKT1/PTEN-altered tumors.

Released: June 4, 2017

Extended intermittent letrozole did not improve DFS or other efficacy outcomes compared with continuous dosing.

Released: June 8, 2017

TC noninferior to EC→T in patients with high-risk HER2-negative early BC with comparable 5-year DFS (90%), OS (95%), and reduced toxicity.

Released: June 12, 2017

The addition of pembrolizumab to neoadjuvant T → AC “graduated” I-SPY 2 for efficacy, approximately tripling the estimated pCR in TNBC and in HR+/HER2- EBC.

Released: June 9, 2017

Comparable pCR, less febrile neutropenia and LVEF decline with anthracycline-free vs anthracycline-containing neoadjuvant CT when paired with dual HER2 blockade.

Released: June 9, 2017

Addition of veliparib and carboplatin to neoadjuvant T → AC did not increase pCR rate over carboplatin plus T → AC alone.

Released: June 7, 2017

Review the latest developments in breast cancer care from ASCO 2017 with these expert insights from Sara Hurvitz, MD, FACP, and Kathy D. Miller, MD.

Sara Hurvitz, MD, FACP Kathy D. Miller, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 16, 2017 Expiration: August 15, 2018

Study data showed significantly prolonged PFS and a lower rate of high-grade adverse events with olaparib monotherapy vs CT.

Released: June 8, 2017

Pertuzumab addition significantly reduced risk of recurrence vs current standard.

Released: June 5, 2017

Gastrointestinal Cancers

In these subanalyses of the CALGB/SWOG 80405 trial, tumor sidedness was a prognostic factor independent of other molecular features, and BRAF status was also a strong prognostic marker for patients with mCRC receiving first-line treatment.

Released: June 14, 2017

In this open-label phase II study, addition of vemurafenib associated with significantly improved PFS and clinical activity in BRAF V600E mCRC patients previously treated with systemic chemotherapy.

Released: June 12, 2017

Next-generation sequencing of circulating tumor DNA revealed complex mutational changes with panitumumab treatment.

Released: June 8, 2017

Lenvatinib demonstrated noninferior OS, significantly increased PFS, TTP, and ORR vs sorafenib with expected safety profile.

Released: June 5, 2017

No significant difference in OS noted, but patients in treated population who received SIRT experienced higher ORR and fewer AEs/serious AEs vs those who received sorafenib.

Released: June 7, 2017

Pembrolizumab well tolerated, produced durable responses in patients with pretreated, advanced gastric/GEJ cancer, with highest responses in PD-L1–positive subgroup.

Released: June 13, 2017

In this trial, adjuvant capecitabine improved survival vs placebo in patients with resected biliary cancer with modest toxicity and no reduction in quality of life.

Released: June 7, 2017

Addition of PEGPH20 to nab-paclitaxel/gemcitabine improved PFS in the full study population with the greatest improvement in the patients with high tumor levels of hyaluronan.

Released: June 6, 2017

AG-120 was associated with fatigue and gastrointestinal toxicities and prolonged stable disease.

Released: June 6, 2017

In this text module and accompanying downloadable slideset, experts Steven J. Cohen, MD, and Alan P. Venook, MD, review the most clinically relevant study results presented at Clinical Oncology 2017 in colorectal cancer, hepatocellular cancer, gastric cancers, biliary cancers, and pancreatic cancer.

Steven J. Cohen, MD Alan P. Venook, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: August 7, 2017 Expiration: August 6, 2018

In this analysis of 6 phase III trials, DFS and neuropathy rates varied with adjuvant oxaliplatin duration among patients based on risk factors and regimen.

Released: June 5, 2017

Genitourinary Cancers

Significant survival benefit and favorable safety profile with pembrolizumab vs chemotherapy maintained in extended follow-up.

Released: June 9, 2017

ORR increased from previous report with longer follow-up and 18-gene GEP score significantly associated with response.

Released: June 8, 2017

In patients with advanced urothelial carcinoma, epacadostat plus pembrolizumab well tolerated, with ORR of 35% (DCR: 53%) in this patient cohort.

Released: June 14, 2017

Adjuvant pazopanib at 600 mg after nephrectomy did not prolong DFS compared with placebo in patients with locally advanced RCC.

Released: June 13, 2017

Epacadostat plus pembrolizumab safe, active in patients with advanced RCC with 47% ORR in patients who received ≤ 1 previous line of therapy.

Released: June 8, 2017

Gynecologic Cancers

In the phase III LION trial, systemic pelvic and para-aortic lymphadenectomy offered no survival benefit and increased postoperative morbidity and mortality in patients with advanced ovarian cancer, macroscopic complete resection, and clinically/radiographically negative lymph nodes.

Released: June 5, 2017

Combination RT + CT improved 5-year failure-free survival by 11% in patients with stage III disease.

Released: June 4, 2017

Nivolumab monotherapy active with a manageable safety profile in recurrent/metastatic cervical, vaginal, or vulvar cancer regardless of PD-L1 expression.

Released: June 4, 2017

No detrimental effect on HRQoL, significant improvement in patient-centered benefits with olaparib vs placebo despite higher olaparib-associated toxicity.

Released: June 13, 2017

Hematologic Malignancies

Momelotinib achieved noninferior spleen response vs rituximab, with inferior total symptom response rate.

Released: June 9, 2017

Results from this phase III study reveal comparable splenic response rate but improved symptomatic response and transfusion independence rates with momelotinib vs BAT.

Released: June 9, 2017

Study investigators conclude that molecular response may predict durable clinical benefit in patients treated with gilteritinib.

Released: June 14, 2017

Enasidenib was associated with durable CRs and low rates of treatment-related grade 3/4 adverse events.

Released: June 12, 2017

Results of 19-28z CAR T-cell treatment in patients with R/R B-cell ALL suggest higher CR rate, extended survival, and reduced toxicity in patients with baseline minimal vs morphologic disease burden.

Released: June 12, 2017

BR associated with significantly increased 5-year PFS, duration of response, and event-free survival vs R-CHOP/R-CVP in overall patient population, particularly in MCL subgroup.

Released: June 5, 2017

Rituximab plus lenalidomide showed activity, tolerable safety in patients with R/R follicular lymphoma, including those with double-refractory disease or early relapse on prior therapy.

Released: June 7, 2017

The addition of ublituximab to ibrutinib improved ORR vs ibrutinib alone with a similar safety profile except for an increase in ublituximab-related infusion reactions.

Released: June 6, 2017

Results from this interim analysis suggest no benefit to radiotherapy in elderly DLBCL patients who are PET negative for bulky disease after immunochemotherapy.

Released: June 8, 2017

Daratumumab addition to standard therapy was associated with an ORR of 100% after median follow-up of 10.8 months.

Released: June 6, 2017

Addition of elotuzumab to RVD associated with high level of overall response in newly diagnosed patients with MM but higher than expected toxicity.

Released: June 7, 2017

KCd use was associated with a lower rate of nonhematologic AEs and improved odds for PBSC mobilization vs KRd use.

Released: June 7, 2017

Results of this large international phase III trial showed that denosumab was associated with significantly less renal toxicity and prolonged PFS vs zoledronic acid in patients with newly diagnosed MM.

Released: June 14, 2017

Phase I results suggest isatuximab-based combination safe, clinically active in highly treatment-experienced R/R MM.

Released: June 8, 2017

In this expert analysis, Sagar Lonial, MD; John M. Burke, MD; and Farhad Ravandi, MD, review key data from the most clinically relevant studies on the management of hematologic malignancies presented at the 2017 Clinical Oncology annual meeting in Chicago.

John M. Burke, MD Sagar Lonial, MD Farhad Ravandi, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: August 18, 2017 Expiration: August 17, 2018

Lung Cancer

Adjuvant gefitinib for up to 2 years achieved superior DFS vs vinorelbine/cisplatin with no cases of interstitial lung disease.

Released: June 7, 2017

Nivolumab with or without ipilimumab associated with durable responses in patients with advanced, previously treated SCLC.

Released: June 7, 2017

Patients with high PD-L1 who started treatment with first-line pembrolizumab achieved better survival outcomes than those starting with first-line chemotherapy.

Released: June 8, 2017

Patients who remained on atezolizumab after progression of disease by RECIST continued to derive benefit.

Released: June 7, 2017

Osimertinib associated with significantly improved CNS disease control vs platinum/pemetrexed in patients with CNS metastases from advanced NSCLC.

Released: June 9, 2017

One half of patients with irAE-related dose interruptions experienced recurrent or new irAEs during immunotherapy retreatment.

Released: June 5, 2017

nab-Paclitaxel–based treatment was active and well tolerated in elderly patients and those with poorer ECOG performance status.

Released: June 5, 2017

Pembrolizumab plus chemotherapy significantly improved ORR and PFS vs chemotherapy alone with comparable safety profile.

Released: June 4, 2017

Matthew D. Hellmann, MD, and Heather Wakelee, MD, examine and discuss key lung cancer and mesothelioma presentations from the 2017 clinical oncology meeting in Chicago.

Matthew D. Hellmann, MD Heather Wakelee, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits Released: August 10, 2017 Expiration: August 9, 2018

Nivolumab with and without ipilimumab was associated with 12-week disease control rates > 40% and median OS > 10 months in patients who progressed after 1-2 lines of chemotherapy.

Released: June 9, 2017

In this phase III study, dacomitinib demonstrated superior PFS and DoR, but with increased toxicity, vs gefitinib in treatment-naive patients with advanced NSCLC and EGFR-activating mutations.

Released: June 9, 2017

Alectinib increased median PFS more than 2-fold and delayed CNS progression with favorable toxicity compared with crizotinib.

Released: June 8, 2017

Skin Cancer

Novel combination of IDO1 inhibitor and immune checkpoint inhibitor proves active in select solid tumors.

Released: June 9, 2017

In a phase II expansion study, the combination had a low incidence of grade 3/4 adverse events across all tumor types evaluated.

Released: June 5, 2017

A nearly 3-year follow-up confirmed superiority of pembrolizumab over ipilimumab in patients with advanced melanoma.

Released: June 5, 2017

First presentation of efficacy data suggests checkpoint inhibitor combination is effective in these patients, with intracranial ORR of 55%.

Released: June 7, 2017

Combination treatment doubled ORR vs ipilimumab alone with no unexpected toxicity.

Released: June 6, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?